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Removal of complement factor D by adsorption on
polymethylmethacrylate dialysis membranes
Sir,
Factor D is the rate-limiting enzyme of the alternative
pathway of complement activation [1]. Similarly to many
other small-molecular-weight proteins, factor D accumulates
in renal failure. The mean concentration of factor D is
1.8ug/ml in normal individuals and approximately 10-fold
higher in patients with end-stage renal failure undergoing
haemodialysis [2]. This increased level of functionally active
factor D is responsible for enhanced activation of the altern-
ative pathway in the plasma of patients with end-stage renal
failure [3]. This situation is particularly unfavourable if one
considers that the blood of such patients is repeatedly
exposed to artificial membranes. Indeed, most dialysis mem-
branes trigger complement activation by the alternative path-
way. Because of its size (24 kDa), factor D is unlikely to be
cleared efficiently during haemodialysis even by highly per-
meable filters. Some dialysis membranes have, however, the
capacity to adsorb proteins. For example, /?2-microglobulin
(12 kDa) is cleared from plasma by adsorption to dialysis
filters made of polyacrylonitrile or polymethylmethacrylate
(PMMA) membranes [4,5].
We investigated whether factor D is adsorbed on PMMA,
in vitro and in vivo. In vitro, normal human serum was
exposed to various quantities of PMMA-BK-P® (pores of
6-8 nm), PMMA-B2® (pores of 1.5-2 nm) or cuprophane
fibres obtained by cutting small fragments of new hollow-
fibre dialysers. Residual haemolytic factor D was measured
after an incubation of 30 min at 37°C [6]. There was a loss
of haemolytic factor D in normal serum exposed to PMMA-
BK-P®, whereas no loss was observed with the other fibres.
This loss was dose-dependent and reached 81% when 75 (il
of serum were incubated with 40 mg of fibres. Removal of
factor D was then monitored in vivo during seven dialysis
sessions of patients on chronic haemodialysis using PMMA-
BK-1.6P® filters.
The factor D levels (corrected for haemoconcentration)
decreased from 24.1 ±7.4 ng/ml to 12.2±3.5 ug/ml
{P<0.005, paired / test) at the end of dialysis (Figure 1),
whereas only a small decrease (from 25.1 ±3.1 ug/ml to
22.7 ±2.6 (j.g/ml, P<0.05) was observed during five dialysis
sessions with cellulose acetate filters (controls, not shown).
The decrease of factor D levels was progressive during
dialysis, and in the same range as that of /!2-microglobulin
(respectively 49.4 ±6.6% and 41.2 + 6.7%). The total amount
of factor D removed per dialysis was calculated to be
approximately 60 mg [6]. Some loss of factor D occurred by
mass transfer of the protein to the dialysate, since 9±2 mg
were recovered in the dialysate from three patients. A similar
mass transfer of factor D was observed when cellulose acetate
filters were used. Thus, most of factor D removal by PMMA-
BK-P® was due to adsorption. This adsorption seems to be
maximal at the beginning of the dialysis session, since samples
of dialysis fluid taken 5 min after the start of dialysis con-
tained no factor D, whereas those taken at 30 min were
positive.
Because of its short half-life, factor D levels in plasma are
rapidly reconstituted after the end of dialysis. The transient
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Fig. 1. Plasma levels of complement factor D before and after
dialysis of patients with PMMA-BK-P* filters.
decrease of factor D might, however, have a favourable effect
by decreasing alternative pathway activation during haemo-
dialysis. Furthermore, a sustained reduction in factor D
levels might be obtained during continuous haemofiltration
as performed in patients with acute renal failure due to sepsis
or other causes. Under such circumstances, a partial decrease
in the activation of the alternative pathway might favourably
affect the outcome of the patient [7]. Other biomaterials
adsorb factor D [8,9]. It appears certainly worthwhile to
develop new biomaterials that down-regulate complement
activation during dialysis.
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OKT3: a therapeutic alternative in recurrence of focal
glomerulosclerosis in the transplanted kidney?
Sir,
The longer survival in renal transplants due to better
immunosuppression has increased interest in recurrence of
primary nephropathies in the graft. In childhood the incid-
ence of post-transplant recurrence of focal segmental glom-
erulosclerosis ranges from 15 to 40%, according to the series
[1,2]. Once the recurrence is diagnosed the deterioration of
the graft is usually rapid, resulting in graft loss. We report a
girl with steroid-resistant nephrotic syndrome due to focal
segmental glomerulosclerosis and its outcome after three
consecutive renal transplants.
A female, 2 years 5 months, who presented with a nephrotic
syndrome resistant to 8 weeks of standard treatment with
prednisone and to one cyclophosphamide course of 8 weeks
is described. The renal biopsy showed a focal segmental
glomerulosclerosis with mesangial proliferation. The condi-
tion progressed to end-stage renal disease 20 months after
onset of the disease. In June 1983 she received a renal graft
from a live related donor, and a bilateral nephrectomy was
performed at the same time. Conventional immunosuppres-
sion with prednisone, beginning with 3 mg/kg per day and
tapering to 0.2 mg/kg per day by 6 months post-
transplantation, and azathioprine (2 mg/kg per day) was
followed. She showed an immediate recurrence with pro-
teinuria >40mg/m2 per hour and hypoalbuminaemia of
2.2 g/dl. A biopsy of the allograft carried out 6 months later
showed focal segmental glomerulosclerosis with mesangial
proliferation, as in the native kidney. Nephrotic syndrome
status was maintained during the entire post-transplant
follow-up, until the reinstitution of dialysis therapy after
11 months.
In April 1985 the patient received a second renal graft
from a cadaver donor. The immunosuppression schedule
included prednisone and cyclosporin (5-7 mg/kg per day)
from the first day. After the fifth transplant day, a massive
proteinuria >40mg/m2 per hour and hypoalbuminaemia
<2.5g/dl appeared. The hypoalbuminaemia was corrected
after 5 months, keeping the proteinuria between 60 and
80 mg/m2 per hour. This time the progressive reduction of
allograft function was slower and led to reinstitution of
dialysis therapy after 44 months. No episode of rejection was
diagnosed. Histological confirmation of recurrence was made
on the allograft nephrectomy.
In March 1991 the patient received a third renal graft
from a cadaver donor. This time the immunosuppression
schedule included OKT3 at 5 mg/day as induction therapy,
beginning at the surgery room and maintained until cyclo-
sporin addition at the 5th day. Immediate diuresis was
established but a similar clinicobiochemical nephrotic syn-
drome developed again within the 12-48 h following surgery.
A complete remission of the nephrotic syndrome was
achieved after the fourth day of OKT3 therapy. Currently,
after 24 months of follow-up, the patient has not had any
Nephrol Dial Transplant 1993: Letters
further proteinuria, keeping steady creatinine levels of
88 umol/1. She remains immunosuppressed with cyclosporin
and prednisone.
The patient showed all the criteria for poor transplant
outcome because of high risk of recurrence: (1) age less than
3 years at the onset of the disease; (2) rapid evolution to
end-stage renal disease; (3) mesangial proliferation in the
renal biopsy; and (4) steroid-resistant nephrotic syndrome.
The immediate evolution in the three consecutive renal grafts
was characterized by the rapid reappearance of nephrotic
syndrome. The course of the second graft, treated with
cyclosporin, was characterized by a partial remission of the
nephrotic syndrome and a slower deterioration of the renal
function. The cyclosporin effect suppressing T lymphocyte
response through the reduction of lymphokine secretion
seems to be the key to its therapeutic action in the nephrotic
syndrome [3,4]. The resolution of the nephrotic syndrome
in the third transplant may be due to a similar effect of
OK.T3 therapy on T lymphocyte function.
Paediatric Nephrology Unit
Hospital Infantil LA FE
Av Campanar, 21
Valencia, Spain
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Haemorrhagic fever with renal syndrome
Sir,
Haemorrhagic fever with renal syndrome (HFRS) is caused
by Hantavirus infection. This virus is thought to be distrib-
uted world-wide, primarily in rodent reservoirs. HFRS is
characterized by fever, hypotension purpura, and interstitial
nephritis [1], It has now been identified in many countries
in Europe and in the United States of America, areas not
previously thought to be endemic for these viruses. Davies
el al. [2] have provided presumptive evidence for the presence
of Hantavirus in Ireland. Although the acute disease appears
to resolve, there is now increasing evidence that residual
renal dysfunction and perhaps progression to chronic renal
failure can ensue. In this regard, 9% (8 of 90) patients on
chronic renal dialysis in Northern Ireland and 2.7% (7 of
254) of chronic dialysis patients in Baltimore, Maryland,
USA were found to have serologic evidence of exposure to
Hantavirus [3,4].
We screened blood samples from 411 renal patients in the
republic of Ireland, of whom 203 were on maintenance
haemodialysis and 207 had a functioning renal transplant.
Patients were studied from all the renal units in Ireland and
thus had both rural and urban distribution. All sera were
screened at 1 in 100 dilutions for IgG antibodies to protype
Hantaan virus by ELISA. Antigen was derived from Vero-E 6
infected cell lysates.
